XML 29 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Data
 12 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segment Data Segment Data
The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional ("Interventional"). The Company’s segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services.
Medical
Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. Medical consists of the following organizational units: Medication Delivery Solutions; Medication Management Solutions; Diabetes Care; Pharmaceutical Systems.
Life Sciences
Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, Life Sciences produces research and clinical tools that facilitate the study of cells, and
the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; public health agencies; physicians’ office practices; retail pharmacies; academic and government institutions; and pharmaceutical and biotechnology companies. With the emergency use authorization approval of the BD Veritor™ At-Home COVID-19 Test, Life Sciences also serves patients directly. Life Sciences consists of the following organizational units: Integrated Diagnostic Solutions and Biosciences.
Interventional
Interventional provides vascular, urology, oncology and surgical specialty products that are intended, with the exception of the V. MuellerTM surgical and laparoscopic instrumentation products, to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by Interventional are hospitals, individual healthcare professionals, extended care facilities, alternate site facilities and patients via the segment's Homecare business. Interventional consists of the following organizational units: Surgery; Peripheral Intervention; Urology and Critical Care.
Additional Segment Information
Distribution of products is primarily through independent distribution channels, and directly to end-users by BD and independent sales representatives. No customer accounted for 10% or more of revenues in any of the three years presented.
Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income, which represents revenues reduced by product costs and operating expenses. The Company’s chief operating decision maker does not receive any asset information by business segment and, as such, the Company does not report asset information by business segment.
Financial information for the Company’s segments is detailed below. The Company has no material intersegment revenues.
(Millions of dollars)202120202019
United StatesInternationalTotalUnited StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions $2,246 $1,812 $4,057 $1,972 $1,583 $3,555 $2,037 $1,811 $3,848 
Medication Management Solutions1,863 570 2,432 1,865 589 2,454 2,115 525 2,640 
Diabetes Care606 554 1,160 562 522 1,084 573 538 1,110 
Pharmaceutical Systems428 1,401 1,829 404 1,184 1,588 392 1,073 1,465 
Total segment revenues$5,142 $4,336 $9,479 $4,802 $3,878 $8,680 $5,116 $3,947 $9,064 
Life Sciences
Integrated Diagnostic Solutions$2,477 $2,748 $5,225 $1,872 $1,659 $3,532 $1,446 $1,659 $3,106 
Biosciences503 802 1,305 465 678 1,143 485 709 1,194 
Total segment revenues$2,980 $3,550 $6,530 $2,337 $2,337 $4,675 $1,931 $2,368 $4,300 
Interventional
Surgery $1,023 $274 $1,296 $891 $230 $1,121 $977 $264 $1,242 
Peripheral Intervention931 780 1,711 871 640 1,511 917 657 1,574 
Urology and Critical Care894 338 1,232 815 315 1,130 787 323 1,110 
Total segment revenues$2,847 $1,392 $4,239 $2,577 $1,186 $3,762 $2,682 $1,244 $3,926 
Total Company revenues$10,969 $9,279 $20,248 $9,716 $7,401 $17,117 $9,730 $7,560 $17,290 
(Millions of dollars)202120202019
Income Before Income Taxes
Medical (a) (b) (c)$2,583 $2,274 $2,824 
Life Sciences (d)2,391 1,405 1,248 
Interventional (e)933 724 903 
Total Segment Operating Income
5,907 4,403 4,976 
Acquisitions and other restructurings(185)(309)(480)
Unallocated other operating expense, net (f)(238)(363)(579)
Net interest expense(460)(521)(627)
Other unallocated items (g)(2,783)(2,224)(2,115)
Total Income Before Income Taxes$2,242 $985 $1,176 
Capital Expenditures
Medical$777 $477 $577 
Life Sciences297 192 230 
Interventional125 119 120 
Corporate and All Other32 22 30 
Total Capital Expenditures$1,231 $810 $957 
Depreciation and Amortization
Medical$1,140 $1,104 $1,073 
Life Sciences352 286 284 
Interventional769 750 881 
Corporate and All Other12 14 14 
Total Depreciation and Amortization$2,273 $2,154 $2,253 
(a)The amounts in 2021 and 2020 include charges of $56 million and $244 million, respectively, recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for BD AlarisTM infusion pumps in the Medication Management Solutions unit.
(b)The amount in 2020 included $41 million of charges to Cost of products sold to write down the value of fixed assets primarily in the Medication Delivery Solutions and Pharmaceutical Systems units.
(c)The amount in 2019 included $75 million of estimated remediation costs recorded to Other operating expense, net relating to a recall of a product component, which generally pre-dated the Company's acquisition of CareFusion in fiscal year 2015, within the Medication Management Solutions unit's infusion systems platform.
(d)The amount in 2020 included charges of $57 million recorded to Cost of products sold to write down the carrying value of certain intangible and other assets in the Biosciences and Integrated Diagnostic Solutions units.
(e)The amount in 2019 included a charge of $30 million recorded to Research and development expense to write down the carrying value of certain intangible assets in the Surgery unit.
(f)The amounts in 2021, 2020 and 2019 include pre-tax charges of $361 million, $378 million and $914 million, respectively, related to certain product liability matters, which is further discussed in Note 5. The amount in 2021 also includes gains of $158 million on sale-leaseback transactions, which are further discussed in Note 17, and $35 million of costs incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business. The 2019 amount also included the pre-tax gain recognized on the Company's sale of its Advanced Bioprocessing business of approximately $336 million, which is further discussed in Note 10.
(g)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.
Geographic Information
The countries in which the Company has local revenue-generating operations have been combined into the following geographic areas: the United States (including Puerto Rico); EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); and Other, which is comprised of Latin America (which includes Mexico, Central America, the Caribbean and South America) and Canada.
Revenues to unaffiliated customers are generally based upon the source of the product shipment. Long-lived assets, which include net property, plant and equipment, are based upon physical location.
(Millions of dollars)202120202019
Revenues
United States$10,969 $9,716 $9,730 
EMEA (a)4,751 3,928 3,837 
Greater Asia3,272 2,568 2,726 
Other (a)1,255 905 997 
$20,248 $17,117 $17,290 
Long-Lived Assets
United States$36,037 $36,468 $37,053 
EMEA (a)6,004 5,890 5,519 
Greater Asia1,662 1,521 1,328 
Other (a)860 753 824 
Corporate465 411 377 
$45,029 $45,043 $45,101 
(a)The amounts in fiscal years 2020 and 2019 reflect the reclassifications of $448 million and $478 million, respectively, of revenues and $55 million and $37 million, respectively, of long-lived assets in the Middle East and Africa.